查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1625398

非酒精性脂肪性肝炎治療市場、規模、佔有率、趨勢、行業分析報告（按藥物、疾病階段、分銷管道和地區）- 市場預測，2025-2034 年

Non-alcoholic Steatohepatitis Treatment Market Size, Share, Trends, Industry Analysis Report: By Drug, Disease Stage, Distribution Channel, and Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 128 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的一項新研究，非酒精性脂肪性肝炎 (NASH) 治療市場規模預計到 2034 年將達到 909.7 億美元。該報告提供了有關當前市場動態的詳細見解，並對未來市場的成長進行了分析。

非酒精性脂肪性肝炎 (NASH) 治療市場的成長歸因於肥胖、2 型糖尿病和代謝症候群等風險因素的日益流行，這些因素與 NASH 的發展密切相關。全球範圍內 NASH 的盛行率日益上升，預計將為製藥公司創造充足的市場機會。

由於針對 NASH 複雜病理生理學（包括肝炎、纖維化和胰島素抗性）的研究力度不斷加大以及創新療法的出現，NASH 治療市場預計將出現強勁的成長軌跡。由於全球NASH發生率的持續上升，尤其是北美、歐洲、亞太等地區，NASH治療的市場規模呈現擴大趨勢。

NASH 治療市場的前景樂觀，多種治療方法正在通過臨床試驗並獲得監管部門的批准，包括奧貝膽酸 (OCA)、索馬魯肽、lanifibranor 和維生素 E。醫療保健機會的擴大、對 NASH 認識的不斷提高以及對肝病的日益關注，都促進了對 NASH 治療的需求不斷增長。此外，人口老化（特別是已開發國家的人口老化）推動了對創新治療的需求。診斷和治療方案的進步將推動大幅擴張，為醫療保健行業的利益相關者提供巨大的成長潛力和機會。

非酒精性脂肪性肝炎治療市場報告重點

按藥物分類，維生素 E 和吡格列酮部分將在 2024 年佔據非酒精性脂肪性肝炎 (NASH) 治療市場收入的最大佔有率，因為它具有抑制肝炎和改善 NASH 患者胰島素敏感性的功效。因為它已經成立了。

基於通路的零售和專業藥房系統部門預計將在預測期內實現最高的複合年增長率，這得益於其易於獲取以及能夠為 NASH 的治療提供專門的藥物和患者支持。

由於肥胖和2 型糖尿病的盛行率高，以及醫療保健基礎設施強大和肝病監測便利，預計到2024 年，北美將佔據非酒精性脂肪性肝炎治療市場佔有率的主導地位。北美擁有大量投資來自

由於醫療保健支出的增加和人們對肝病管理的認識的不斷提高，預計亞太市場在預測期內將出現顯著增長。

全球市場的主要參與者是 Intercept Pharmaceuticals, Inc.；Galmed Pharmaceuticals Ltd；Inventiva；AbbVie Inc.；Galectin Therapeutics Inc.；Madrigal Pharmaceuticals Inc (Madrigal)；NGM Biopharmaceuticals, Inc.；Novo Nordisk A/S ；百時美施貴寶公司；以及吉利德科學公司。

目錄

第 1 章簡介

第 2 章執行摘要

第 3 章 研究方法

第 4 章全球非酒精性脂肪肝炎治療市場洞察

  • 市場概況
  • 非酒精性脂肪性肝炎治療市場動態
    • 推動因素和機遇
      • 老年人口增加
      • 2 型糖尿病發生率不斷上升
    • 阻礙因素和課題
      • 醫療費用高昂
  • PESTEL 分析
  • 非酒精性脂肪性肝炎治療市場趨勢
  • 價值鏈分析
  • COVID-19 影響分析

第5章 全球非酒精性脂肪性肝炎治療市場（依藥物類型）

  • 主要發現
  • 簡介
  • 維生素 E 和吡格列酮 奧貝膽酸 (OCA)
  • 拉尼菲布蘭諾
  • 索馬魯肽
  • Resmetirom
  • 阿拉姆喬爾
  • 塞尼克裡維羅克
  • 其他藥物

第6章 全球非酒精性脂肪肝炎治療市場（依疾病階段）

  • 主要發現
  • 簡介
  • NASH F0 期
  • NASH F1 期
  • NASH F2 期
  • NASH F3 期
  • NASH F4 期

第7章 全球非酒精性脂肪肝炎治療市場（依通路）

  • 主要發現
  • 簡介
  • 醫院藥房
  • 零售與專業藥局
  • 其他藥局

第 8 章全球非酒精性脂肪肝炎治療市場（按地區）

  • 主要發現
  • 簡介
    • 2020 年至 2034 年非酒精性脂肪性肝炎治療市場各地區評估
  • 北美洲
    • 2020 年至 2034 年，北美各藥物狀況 北美：疾病階段，2020 - 2034 年 2020 年至 2034 年北美按通路劃分
    • 美國
    • 加拿大
  • 歐洲
      2020 年至 2034 年歐洲藥物狀況 歐洲：疾病階段，2020 - 2034 年 2020 年至 2034 年歐洲按通路劃分
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 荷蘭
    • 俄羅斯
    • 其他歐洲國家
    亞太地區
      2020 年至 2034 年亞太地區藥物類型 2020 年至 2034 年亞太地區疾病分期 2020 年至 2034 年亞太地區通路分佈
    • 中國
    • 印度
    • 馬來西亞
    • 日本
    • 印尼
    • 韓國
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲
      中東和非洲：按藥物分類，2020 年至 2034 年 中東和非洲：疾病階段，2020 年至 2034 年 2020 年至 2034 年中東和非洲按分銷管道劃分
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 南非
    • 其他中東和非洲地區
  • 拉丁美洲
    • 拉丁美洲，依藥物分類，2020 年至 2034 年
    • 2020 年至 2034 年拉丁美洲各疾病階段狀況 2020 年至 2034 年拉丁美洲按通路劃分
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家

第 9 章 競爭格局

  • 擴張與收購分析
    • 放大
    • 收購
  • 夥伴關係/協作/協定/揭露

第10章 公司簡介

  • Intercept Pharmaceuticals, Inc.
  • Galmed Pharmaceuticals Ltd
  • Inventiva
  • AbbVie Inc.
  • Galectin Therapeutics Inc.
  • Madrigal Pharmaceuticals Inc.（Madrigal）
  • NGM Biopharmaceuticals, Inc.
  • Novo Nordisk A/S
  • The Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
Product Code: PM5283

The non-alcoholic steatohepatitis treatment market size is expected to reach USD 90.97 billion by 2034, according to a new study by Polaris Market Research. The report "Non-alcoholic Steatohepatitis Treatment Market Share, Size, Trends, Industry Analysis Report: By Drug, Disease Stage, Distribution Channel (Hospital Pharmacies, Retail and Specialty Pharmacies, and Other Pharmacies), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The non-alcoholic steatohepatitis (NASH) treatment market growth is attributed to the rising prevalence of risk factors such as obesity, type 2 diabetes, and metabolic syndrome, strongly linked to the development of NASH. The rising prevalence of NASH across the world is expected to create ample market opportunities for pharmaceutical companies.

The NASH treatment market is expected to experience a robust growth trajectory, increasing research efforts and innovative therapies targeting the complex pathophysiology of NASH, including liver inflammation, fibrosis, and insulin resistance. The market size for NASH treatments is expanding, with the global incidence of NASH continuing to rise, particularly in regions such as North America, Europe, and Asia Pacific.

The non-alcoholic steatohepatitis treatment market outlook is optimistic, with a growing number of drugs, including Obeticholic Acid (OCA), Semaglutide, Lanifibranor, and Vitamin E, advancing through clinical trials and receiving regulatory approvals. The expansion of healthcare access, increased awareness about NASH, and the growing focus on liver diseases contribute to the rising demand for NASH treatments. Moreover, the aging population, especially in developed countries, accelerates the need for innovative therapies. Advancements in diagnostics and treatment options are set to drive significant expansion, offering considerable growth potential and opportunities for stakeholders within the healthcare industry.

Non-alcoholic Steatohepatitis Treatment Market Report Highlights

In terms of drug, in 2024, the vitamin E and pioglitazone segment accounted for the largest share of the non-alcoholic steatohepatitis (NASH) treatment market revenue due to its well-established efficacy in reducing liver inflammation and improving insulin sensitivity in NASH patients.

The retail and specialty pharmacies systems segment, based on distribution channel, is expected to witness the highest CAGR during the forecast period due to its accessibility and ability to provide specialized medications and patient support for NASH treatment.

In 2024, North America dominated the non-alcoholic steatohepatitis treatment market share due to the high prevalence of obesity and type 2 diabetes, coupled with strong healthcare infrastructure and substantial investment in liver disease research.

The Asia Pacific market is expected to witness significant growth during the forecast period due to increasing healthcare expenditure and greater awareness of liver disease management.

A few global key market players are Intercept Pharmaceuticals, Inc.; Galmed Pharmaceuticals Ltd; Inventiva; AbbVie Inc.; Galectin Therapeutics Inc.; Madrigal Pharmaceuticals Inc (Madrigal); NGM Biopharmaceuticals, Inc.; Novo Nordisk A/S; The Bristol-Myers Squibb Company; and Gilead Sciences, Inc.

Polaris Market Research has segmented the non-alcoholic steatohepatitis treatment market report on the basis of drug, disease stage, distribution channel, and region:

By Drug Outlook (Revenue, USD Billion; 2020-2034)

  • Vitamin E and Pioglitazone
  • Obeticholic Acid (OCA)
  • Lanifibranor
  • Semaglutide
  • Resmetirom
  • Aramchol
  • Cenicriviroc
  • Other Drugs

By Disease Stage Outlook (Revenue, USD Billion; 2020-2034)

  • NASH Stage F0
  • NASH Stage F1
  • NASH Stage F2
  • NASH Stage F3
  • NASH Stage F4

By Distribution Channel Outlook (Revenue, USD Billion; 2020-2034)

  • Hospital Pharmacies
  • Retail and Specialty Pharmacies
  • Other Pharmacies

By Regional Outlook (Revenue, USD Billion; 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Non-alcoholic Steatohepatitis Treatment Market Insights

  • 4.1. Non-alcoholic Steatohepatitis Treatment Market - Market Snapshot
  • 4.2. Non-alcoholic Steatohepatitis Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Aging Population
      • 4.2.1.2. Rising Incidence of Type 2 Diabetes
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Treatment Costs
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Non-alcoholic Steatohepatitis Treatment Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Non-alcoholic Steatohepatitis Treatment Market, by Drug

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
  • 5.3. Vitamin E and Pioglitazone
    • 5.3.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Vitamin E and Pioglitazone, by Region, 2020-2034 (USD Billion)
  • 5.4. Obeticholic Acid (OCA)
    • 5.4.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Obeticholic Acid (OCA), by Region, 2020-2034 (USD Billion)
  • 5.5. Lanifibranor
    • 5.5.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Lanifibranor, by Region, 2020-2034 (USD Billion)
  • 5.6. Semaglutide
    • 5.6.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Semaglutide, by Region, 2020-2034 (USD Billion)
  • 5.7. Resmetirom
    • 5.7.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Resmetirom, by Region, 2020-2034 (USD Billion)
  • 5.8. Aramchol
    • 5.8.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Aramchol, by Region, 2020-2034 (USD Billion)
  • 5.9. Cenicriviroc
    • 5.9.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Cenicriviroc, by Region, 2020-2034 (USD Billion)
  • 5.10. Other Drugs
    • 5.10.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Other Drugs, by Region, 2020-2034 (USD Billion)

6. Global Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
  • 6.3. NASH Stage F0
    • 6.3.1. Global Non-alcoholic Steatohepatitis Treatment Market, by NASH Stage F0, by Region, 2020-2034 (USD Billion)
  • 6.4. NASH Stage F1
    • 6.4.1. Global Non-alcoholic Steatohepatitis Treatment Market, by NASH Stage F1, by Region, 2020-2034 (USD Billion)
  • 6.5. NASH Stage F2
    • 6.5.1. Global Non-alcoholic Steatohepatitis Treatment Market, by NASH Stage F2, by Region, 2020-2034 (USD Billion)
  • 6.6. NASH Stage F3
    • 6.6.1. Global Non-alcoholic Steatohepatitis Treatment Market, by NASH Stage F3, by Region, 2020-2034 (USD Billion)
  • 6.7. NASH Stage F4
    • 6.7.1. Global Non-alcoholic Steatohepatitis Treatment Market, by NASH Stage F4, by Region, 2020-2034 (USD Billion)

7. Global Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Hospital Pharmacies, by Region, 2020-2034 (USD Billion)
  • 7.4. Retail and Specialty Pharmacies
    • 7.4.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Retail and Specialty Pharmacies, by Region, 2020-2034 (USD Billion)
  • 7.5. Other Pharmacies
    • 7.5.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Other Pharmacies, by Region, 2020-2034 (USD Billion)

8. Global Non-alcoholic Steatohepatitis Treatment Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Non-alcoholic Steatohepatitis Treatment Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 8.3. Non-alcoholic Steatohepatitis Treatment Market - North America
    • 8.3.1. North America: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
    • 8.3.2. North America: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
    • 8.3.3. North America: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.3.4. Non-alcoholic Steatohepatitis Treatment Market - U.S.
      • 8.3.4.1. U.S.: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.3.4.2. U.S.: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.3.4.3. U.S.: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.3.5. Non-alcoholic Steatohepatitis Treatment Market - Canada
      • 8.3.5.1. Canada: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.3.5.2. Canada: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.3.5.3. Canada: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.4. Non-alcoholic Steatohepatitis Treatment Market - Europe
    • 8.4.1. Europe: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
    • 8.4.2. Europe: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
    • 8.4.3. Europe: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.4. Non-alcoholic Steatohepatitis Treatment Market - UK
      • 8.4.4.1. UK: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.4.2. UK: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.4.3. UK: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.5. Non-alcoholic Steatohepatitis Treatment Market - France
      • 8.4.5.1. France: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.5.2. France: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.5.3. France: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.6. Non-alcoholic Steatohepatitis Treatment Market - Germany
      • 8.4.6.1. Germany: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.6.2. Germany: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.6.3. Germany: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.7. Non-alcoholic Steatohepatitis Treatment Market - Italy
      • 8.4.7.1. Italy: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.7.2. Italy: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.7.3. Italy: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.8. Non-alcoholic Steatohepatitis Treatment Market - Spain
      • 8.4.8.1. Spain: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.8.2. Spain: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.8.3. Spain: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.9. Non-alcoholic Steatohepatitis Treatment Market - Netherlands
      • 8.4.9.1. Netherlands: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.9.2. Netherlands: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.9.3. Netherlands: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.10. Non-alcoholic Steatohepatitis Treatment Market - Russia
      • 8.4.10.1. Russia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.10.2. Russia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.10.3. Russia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.11. Non-alcoholic Steatohepatitis Treatment Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.11.2. Rest of Europe: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.11.3. Rest of Europe: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.5. Non-alcoholic Steatohepatitis Treatment Market - Asia Pacific
    • 8.5.1. Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
    • 8.5.2. Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
    • 8.5.3. Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.4. Non-alcoholic Steatohepatitis Treatment Market - China
      • 8.5.4.1. China: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.4.2. China: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.4.3. China: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.5. Non-alcoholic Steatohepatitis Treatment Market - India
      • 8.5.5.1. India: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.5.2. India: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.5.3. India: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.6. Non-alcoholic Steatohepatitis Treatment Market - Malaysia
      • 8.5.6.1. Malaysia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.6.2. Malaysia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.6.3. Malaysia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.7. Non-alcoholic Steatohepatitis Treatment Market - Japan
      • 8.5.7.1. Japan: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.7.2. Japan: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.7.3. Japan: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.8. Non-alcoholic Steatohepatitis Treatment Market - Indonesia
      • 8.5.8.1. Indonesia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.8.2. Indonesia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.8.3. Indonesia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.9. Non-alcoholic Steatohepatitis Treatment Market - South Korea
      • 8.5.9.1. South Korea: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.9.2. South Korea: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.9.3. South Korea: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.10. Non-alcoholic Steatohepatitis Treatment Market - Australia
      • 8.5.10.1. Australia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.10.2. Australia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.10.3. Australia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.11. Non-alcoholic Steatohepatitis Treatment Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.11.2. Rest of Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.11.3. Rest of Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.6. Non-alcoholic Steatohepatitis Treatment Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
    • 8.6.2. Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
    • 8.6.3. Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.4. Non-alcoholic Steatohepatitis Treatment Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.6.4.2. Saudi Arabia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.5. Non-alcoholic Steatohepatitis Treatment Market - UAE
      • 8.6.5.1. UAE: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.6.5.2. UAE: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.6.5.3. UAE: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.6. Non-alcoholic Steatohepatitis Treatment Market - Israel
      • 8.6.6.1. Israel: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.6.6.2. Israel: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.6.6.3. Israel: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.7. Non-alcoholic Steatohepatitis Treatment Market - South Africa
      • 8.6.7.1. South Africa: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.6.7.2. South Africa: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.6.7.3. South Africa: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.8. Non-alcoholic Steatohepatitis Treatment Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.6.8.2. Rest of Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.6.8.3. Rest of Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.7. Non-alcoholic Steatohepatitis Treatment Market - Latin America
    • 8.7.1. Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
    • 8.7.2. Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
    • 8.7.3. Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.4. Non-alcoholic Steatohepatitis Treatment Market - Mexico
      • 8.7.4.1. Mexico: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.7.4.2. Mexico: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.7.4.3. Mexico: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.5. Non-alcoholic Steatohepatitis Treatment Market - Brazil
      • 8.7.5.1. Brazil: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.7.5.2. Brazil: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.7.5.3. Brazil: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.6. Non-alcoholic Steatohepatitis Treatment Market - Argentina
      • 8.7.6.1. Argentina: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.7.6.2. Argentina: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.7.6.3. Argentina: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.7. Non-alcoholic Steatohepatitis Treatment Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.7.7.2. Rest of Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.7.7.3. Rest of Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Intercept Pharmaceuticals, Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Galmed Pharmaceuticals Ltd
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Inventiva
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. AbbVie Inc.
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Galectin Therapeutics Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Madrigal Pharmaceuticals Inc. (Madrigal)
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. NGM Biopharmaceuticals, Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Novo Nordisk A/S
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. The Bristol-Myers Squibb Company
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Gilead Sciences, Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development

List of Tables:

Table 1 Global Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 2 Global Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 3 Global Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 4 North America: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 5 North America: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 6 North America: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 7 U.S.: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 8 U.S.: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 9 U.S.: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 10 Canada: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 11 Canada: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 12 Canada: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 13 Europe: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 14 Europe: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 15 Europe: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 16 UK: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 17 UK: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 18 UK: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 19 France: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 20 France: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 21 France: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 22 Germany: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 23 Germany: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 24 Germany: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 25 Italy: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 26 Italy: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 27 Italy: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 28 Spain: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 29 Spain: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 30 Spain: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 31 Netherlands: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 32 Netherlands: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 33 Netherlands: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 34 Russia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 35 Russia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 36 Russia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 37 Rest of Europe: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 38 Rest of Europe: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 39 Rest of Europe: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 40 Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 41 Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 42 Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 43 China: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 44 China: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 45 China: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 46 India: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 47 India: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 48 India: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 49 Malaysia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 50 Malaysia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 51 Malaysia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 52 Japan: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 53 Japan: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 54 Japan: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 55 Indonesia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 56 Indonesia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 57 Indonesia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 58 South Korea: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 59 South Korea: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 60 South Korea: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 61 Australia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 62 Australia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 63 Australia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 64 Rest of Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 65 Rest of Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 66 Rest of Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 67 Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 68 Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 69 Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 70 Saudi Arabia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 71 Saudi Arabia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 72 Saudi Arabia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 73 UAE: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 74 UAE: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 75 UAE: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 76 Israel: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 77 Israel: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 78 Israel: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 79 South Africa: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 80 South Africa: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 81 South Africa: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 82 Rest of Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 83 Rest of Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 84 Rest of Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 85 Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 86 Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 87 Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 88 Mexico: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 89 Mexico: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 90 Mexico: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 91 Brazil: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 92 Brazil: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 93 Brazil: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 94 Argentina: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 95 Argentina: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 96 Argentina: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 97 Rest of Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 98 Rest of Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 99 Rest of Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

List of Figures:

Figure 1. Global Non-alcoholic Steatohepatitis Treatment Market, 2020-2034 (USD Billion)

Figure 2. Integrated Ecosystem

Figure 3. Research Methodology: Top-Down & Bottom-Up Price

Figure 4. Market by Geography

Figure 5. Porter's Five Forces

Figure 6. Market by Drug

Figure 7. Global Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2024 & 2034 (USD Billion)

Figure 8. Market by Disease Stage

Figure 9. Global Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2024 & 2034 (USD Billion)

Figure 10. Market by Distribution Channel

Figure 11. Global Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2024 & 2034 (USD Billion)